Agios scores its second new drug approval, ivosidenib heads to the AML market
Agios has hit another big goal in its decade-long track record. The FDA today signaled the accelerated approval of ivosidenib (AG-120) for advanced acute myeloid leukemia.
This marks the second drug approval for Agios, a biotech company founded by David Schenkein, which he’s fond of saying got started with a “blank sheet of paper.”
That sheet is getting quite crowded now.
The new drug will be marketed by Agios as Tibsovo, and the company is charging $26,115 for a one-month supply. Agios shares $AGIO were down just slightly — this was no great surprise — but the stock is up 56% 0f where it was a year ago.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.